MIRM,DAWN,VIR Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +1.73
Percentage change 3.87	%

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-1.61	Insider Own	19.00%	Shs Outstand	49.45M	Perf Week	4.32%
Market Cap	2.30B	Forward P/E	-	EPS next Y	-0.49	Insider Trans	-2.01%	Shs Float	40.12M	Perf Month	12.52%
Income	-77.34M	PEG	-	EPS next Q	-0.33	Inst Own	93.48%	Short Float	15.67%	Perf Quarter	6.72%
Sales	379.25M	P/S	6.06	EPS this Y	39.83%	Inst Trans	1.80%	Short Ratio	14.42	Perf Half Y	1.74%
Book/sh	4.72	P/B	9.83	EPS next Y	56.25%	ROA	-11.52%	Short Interest	6.29M	Perf Year	79.84%
Cash/sh	5.61	P/C	8.27	EPS next 5Y	-	ROE	-33.06%	52W Range	24.07 - 54.23	Perf YTD	12.16%
Dividend Est.	-	P/FCF	-	EPS past 5Y	4.14%	ROI	-14.09%	52W High	-14.48%	Beta	0.95
Dividend TTM	-	Quick Ratio	3.04	Sales past 5Y	-	Gross Margin	76.99%	52W Low	92.69%	ATR (14)	1.57
Dividend Ex-Date	-	Current Ratio	3.22	EPS Y/Y TTM	57.12%	Oper. Margin	-20.12%	RSI (14)	61.17	Volatility	2.50% 1.77%
Employees	322	Debt/Eq	1.36	Sales Y/Y TTM	69.31%	Profit Margin	-20.39%	Recom	1.10	Target Price	68.60
Option/Short	Yes / Yes	LT Debt/Eq	1.35	EPS Q/Q	44.27%	Payout	-	Rel Volume	0.63	Prev Close	44.65
Sales Surprise	13.38%	EPS Surprise	9.06%	Sales Q/Q	61.20%	Earnings	May 07 AMC	Avg Volume	436.09K	Price	46.38
SMA20	3.60%	SMA50	7.96%	SMA200	6.75%	Trades		Volume	272,949	Change	3.87%

Date	Action	Analyst	Rating Change	Price Target Change
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Loading…
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
06:45PM	Loading…
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
05:15PM	Loading…
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)
07:31AM	Mirum drug for rare genetic disease gains FDA approval (BioPharma Dive)
Feb-19-25 04:04PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 (Business Wire)
Feb-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-24-25 12:00PM	Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-14-25 08:50AM	Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-13-25 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates (Business Wire) +6.49%
Jan-10-25 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-25 04:04PM	Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? (Zacks)
Dec-10-24 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-06-24 06:46AM	Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities (TipRanks)
Nov-14-24 08:00AM	Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire) +5.33%
Nov-13-24 02:09AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Nov-12-24 09:15AM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-08-24 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 04:30PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-04-24 04:30PM	Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (Business Wire)
Oct-31-24 10:02AM	Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:30AM	Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Oct-23-24 08:49AM	Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth (Insider Monkey)
Oct-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis (Business Wire)
Oct-09-24 05:18PM	Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Sep-10-24 08:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
11:31AM	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-19-24 11:06AM	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern (Zacks)
Aug-09-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.79%
Aug-08-24 11:01AM	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
Aug-07-24 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 04:30PM	Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 (Business Wire)
Jul-29-24 07:28AM	Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains? (Zacks)
Jul-25-24 08:30AM	Mirums LIVMARLI Now Approved for PFIC in Patients 12 Months and Older (Business Wire)
Jul-12-24 01:22PM	Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves (Investor's Business Daily)
Jul-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-24 10:37AM	Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion (Zacks)
Jul-08-24 11:38AM	Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why (Zacks)
08:30AM	Mirum Pharmaceuticals LIVMARLI Approved in the European Union for Patients with PFIC (Business Wire)
Jun-28-24 02:26PM	MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50 (Investor's Business Daily)
08:30AM	Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX (Business Wire)
Jun-25-24 11:31AM	Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling (Investor's Business Daily)
Jun-18-24 11:14AM	Mirum (MIRM) Soars on Interim Data From Liver Disease Studies (Zacks) -11.36%
05:46AM	Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-17-24 08:00AM	Mirums Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies (Business Wire) +27.31%
Jun-16-24 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 (Business Wire)
Jun-10-24 10:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-07-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report? (Zacks)
Jun-06-24 09:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress (Business Wire) -5.10%
Jun-05-24 04:05PM	Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
Jun-03-24 06:46AM	EMA CHMP endorses Mirum Pharmaceuticals LIVMARLI for PFIC (Pharmaceutical Technology) +5.49%
May-31-24 08:30AM	Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older (Business Wire)
May-29-24 08:30AM	Long-Term Data from Mirums LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress (Business Wire)
May-28-24 10:02AM	Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns (Zacks)
May-18-24 07:00AM	Mirum Pharmaceuticals LIVMARLI Data Showcased at ESPGHAN Annual Meeting (Business Wire)
May-13-24 09:40AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:55PM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss (GuruFocus.com)
01:12PM	Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating (MT Newswires)
May-09-24 11:46AM	Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates (Zacks)
07:40AM	Q1 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:49AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ... (GuruFocus.com)
May-08-24 04:02PM	Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM
Radovich Peter	PRESIDENT AND COO	Feb 03 '25	Sale	48.22	2,627	126,681	26,961	Feb 04 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 03 '25	Sale	48.22	9,102	438,921	115,920	Feb 04 05:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 03 '25	Sale	48.22	1,064	51,309	4,232	Feb 04 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 24 '25	Sale	47.92	3,177	152,256	29,588	Jan 27 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 24 '25	Sale	47.92	902	43,228	3,524	Jan 27 04:48 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 24 '25	Sale	47.92	6,837	327,658	125,022	Jan 27 04:48 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 17 '25	Sale	45.86	6,969	319,598	5,649	Jan 21 04:21 PM
Radovich Peter	PRESIDENT AND COO	Jan 07 '25	Sale	42.82	1,998	85,545	27,015	Jan 08 04:44 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	42.82	7,489	320,644	119,359	Jan 08 04:42 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 07 '25	Sale	42.82	750	32,111	2,926	Jan 08 04:38 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Option Exercise	2.94	2,500	7,350	4,926	Nov 15 05:34 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Sale	47.10	2,500	117,752	2,426	Nov 15 05:34 PM
Heron Patrick J	Director	Sep 18 '24	Buy	37.40	115	4,301	162,308	Sep 20 04:39 PM
Heron Patrick J	Director	Sep 06 '24	Buy	41.58	230	9,563	162,193	Sep 10 05:04 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jul 23 '24	Option Exercise	2.94	34,013	99,862	126,783	Jul 24 05:32 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '24	Sale	34.00	375	12,750	2,426	Jul 03 06:19 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Option Exercise	2.94	30,559	89,721	57,965	Jun 25 05:15 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Jun 24 '24	Sale	34.00	30,559	1,039,006	27,406	Jun 25 05:15 PM

Dollar change +0.24
Percentage change 3.45	%

DAWN Day One Biopharmaceuticals Inc daily Stock Chart

Peers: VRTX NBIX BPMC SRPT EXEL FATE IGMS KURA BHVN PBYI

| Held by: VTI XBI IWM VXF VB VBR IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.67	Insider Own	26.34%	Shs Outstand	101.35M	Perf Week	12.70%
Market Cap	728.80M	Forward P/E	-	EPS next Y	-0.84	Insider Trans	-0.29%	Shs Float	74.66M	Perf Month	14.13%
Income	-69.08M	PEG	-	EPS next Q	-0.35	Inst Own	84.00%	Short Float	24.68%	Perf Quarter	-17.07%
Sales	161.92M	P/S	4.50	EPS this Y	-35.23%	Inst Trans	0.46%	Short Ratio	14.40	Perf Half Y	-47.09%
Book/sh	4.73	P/B	1.52	EPS next Y	39.36%	ROA	-16.05%	Short Interest	18.42M	Perf Year	-43.70%
Cash/sh	4.67	P/C	1.54	EPS next 5Y	-	ROE	-17.80%	52W Range	6.08 - 16.76	Perf YTD	-43.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-38.09%	ROI	-14.32%	52W High	-57.10%	Beta	-1.30
Dividend TTM	-	Quick Ratio	10.55	Sales past 5Y	-	Gross Margin	94.96%	52W Low	18.26%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	10.62	EPS Y/Y TTM	73.23%	Oper. Margin	-118.31%	RSI (14)	57.86	Volatility	1.89% 3.19%
Employees	181	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-42.66%	Recom	1.22	Target Price	28.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	51.32%	Payout	-	Rel Volume	1.13	Prev Close	6.95
Sales Surprise	1.63%	EPS Surprise	20.07%	Sales Q/Q	-	Earnings	May 06 AMC	Avg Volume	1.28M	Price	7.19
SMA20	10.29%	SMA50	2.19%	SMA200	-36.71%	Trades		Volume	1,445,729	Change	3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-24	Reiterated	Needham	Buy	$32 → $33
Aug-01-24	Upgrade	BofA Securities	Underperform → Buy	$11 → $24
Apr-24-24	Reiterated	Needham	Buy	$30 → $33
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform	$34 → $9
Feb-08-23	Initiated	CapitalOne	Overweight	$40
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy	$35
Dec-14-22	Initiated	Needham	Buy	$40
Dec-05-22	Initiated	Goldman	Buy	$45
Dec-01-22	Initiated	BofA Securities	Buy	$34

May-13-25 10:47AM	Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey)
May-09-25 07:54AM	Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-07-25 11:09AM	Q1 2025 Day One Biopharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.87%
03:21AM	Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-06-25 05:25PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.55%
04:01PM	Loading…
04:01PM	Day One Reports First Quarter 2025 Financial Results and Corporate Progress (GlobeNewswire)
May-05-25 10:00AM	Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com) -5.67%
May-03-25 02:13AM	Q1 2025 American International Group Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-23-25 02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-22-25 08:30AM	Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025 (GlobeNewswire)
Apr-10-25 11:51PM	Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity (Seeking Alpha) -7.02% +5.33%
Apr-09-25 09:44AM	Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple (Insider Monkey) +8.35%
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Mar-20-25 01:00AM	EXCLUSIVE: Plant Medicine Brand Apothékary Is Taking Customers on a $10,000 Immersive Trip to Japan (WWD)
Mar-05-25 09:00AM	Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory (Insider Monkey) +12.79%
05:55PM	Loading…
Feb-25-25 05:55PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -16.50%
04:05PM	Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress (GlobeNewswire)
01:36AM	Day One Biopharmaceuticals Inc (DAWN) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-13-25 09:55AM	Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect? (Zacks)
Feb-11-25 08:30AM	Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 (GlobeNewswire)
Jan-28-25 08:56AM	Trump pledged to bring down food prices on Day One. Instead, eggs are getting more expensive (CNN Business)
05:30AM	Trump said hed bring prices down on Day One. That hasnt happened (CNN Business)
Jan-23-25 01:02AM	Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? (Insider Monkey)
Jan-22-25 08:44AM	New Tariffs Didnt Come on Trumps Day One. A Trade War May Not Be in the Wings. (Barrons.com)
Jan-20-25 03:31PM	President Trump outlines a frenzy of Day One executive orders and actions: Heres a list of what to expect (FastCompany)
Jan-13-25 08:00AM	Day One Reports Preliminary 2024 OJEMDA Net Product Revenue and Highlights 2025 Corporate Priorities (GlobeNewswire)
Dec-24-24 04:30PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-22-24 03:30PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-19-24 03:19PM	Are These AI Stocks Ready for a Comeback? (InvestorPlace)
Dec-17-24 08:30AM	Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:49AM	Loading…
Dec-16-24 09:49AM	How Trump Can Help Crypto on Day One (CoinDesk)
Dec-06-24 08:53PM	Instagram locks out developers of third-party consumer apps (TechCrunch)
Nov-27-24 10:18AM	Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts? (Insider Monkey)
Nov-20-24 04:30PM	Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development (GlobeNewswire)
Nov-18-24 08:30AM	Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? (Zacks)
Oct-30-24 05:20PM	Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Day One Reports Third Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
Oct-21-24 09:55AM	Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 140.71%: Read This Before Placing a Bet (Zacks)
Oct-16-24 08:44AM	Day One Biopharmaceuticals (DAWN): Advancing Targeted Therapies for Pediatric Glioma (Insider Monkey)
08:30AM	Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 (GlobeNewswire)
Oct-01-24 08:00PM	At What Oil Price Will Shale Drillers Stop Drilling? (Oilprice.com)
Aug-27-24 12:49PM	Taylor Fritzs Girlfriend Morgan Riddle Opts for Classic Little Black Dress on Day One of the U.S. Open 2024 (WWD)
Aug-19-24 11:15AM	Jeff Bezos Said 'I Predict One Day Amazon Will Fail' And Claims Large Companies Only Last '30-Plus Years' Guess How Old Amazon Is? (Benzinga)
Aug-14-24 11:46AM	Bank of America Says Buy These 3 Stocks for a Double-Digit Rally (InvestorPlace)
Jul-30-24 01:52PM	DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
08:40AM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Day One Reports Second Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
07:00AM	Day One Announces Oversubscribed $175.0 Million Private Placement (GlobeNewswire)
Jul-25-24 11:53AM	Ipsen outlines $461m for ex-US rights to Day Ones glioma therapy (Pharmaceutical Technology)
12:58AM	Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor (GlobeNewswire)
Jun-27-24 09:51AM	Lupita Nyongo Shimmers in Sequined Off-the-shoulder Prada Jumpsuit and Satin Miniskirt at A Quiet Place: Day One Premiere (WWD)
Jun-24-24 04:50PM	Lupita Nyongo Gives Power Suiting a Sensual Spin in Double-breasted Blazer and High-waisted Shorts for A Quiet Place: Day One Photo Call (WWD)
Jun-22-24 04:11AM	Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN) (GuruFocus.com)
Jun-19-24 12:14PM	Day One targets the growing ADC market with MabCare acquisition (Pharmaceutical Technology)
10:29AM	Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up (Zacks)
Jun-18-24 08:30AM	Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers (GlobeNewswire) +11.31%
Jun-11-24 07:46AM	Exclusive: Day One Ventures closes its third fund at $150 million (Fortune)
May-30-24 08:30AM	Day One Announces Sale of Priority Review Voucher for $108 Million (GlobeNewswire)
May-07-24 09:25AM	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating (MT Newswires)
May-06-24 10:53PM	DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024 (InvestorPlace)
04:30PM	Day One Reports First Quarter 2024 Financial Results and Corporate Progress (GlobeNewswire)
03:22AM	Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing (MT Newswires)
May-04-24 02:31AM	Insider Sale at Day One Biopharmaceuticals Inc (DAWN) (GuruFocus.com)
Apr-23-24 03:56PM	Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor (GlobeNewswire) +8.19%
03:54PM	Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment (MT Newswires)
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-28-24 04:32AM	Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Feb-26-24 04:30PM	Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress (GlobeNewswire) +11.05%
Jan-31-24 05:12PM	Dwayne 'The Rock' Johnson's net worth: How the new TKO Board Member built his wealth from $7 (TheStreet)
Jan-17-24 08:00AM	Day One Announces Two New Appointments to Board of Directors (GlobeNewswire)
Dec-19-23 08:00AM	Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-27-23 10:00AM	Milei to Send Shock Package to Argentinas Congress on Day One (Bloomberg)
Nov-17-23 07:00AM	Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine (GlobeNewswire)
Nov-14-23 08:00AM	Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire) +6.85%
Nov-06-23 05:16PM	Day One Biopharmaceuticals Inc (DAWN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
04:30PM	Day One Reports Third Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-30-23 07:27PM	Apples Journal app has arrived heres whats good and bad (TechCrunch) +17.01%
08:00AM	Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Oct-23-23 01:20PM	Hedge Fund and Insider Trading News: Bill Ackman, Nelson Peltz, Dan Loeb, Coltrane Asset Management, Day One Biopharmaceuticals, Inc. (DAWN), Central Securities Corp. (CET), and More (Insider Monkey)
Oct-20-23 10:20AM	Tesla Stock Had a Horrible Day. Heres What Comes Next. (Barrons.com)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-11-23 09:02PM	Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Aug-16-23 08:00AM	Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience (GlobeNewswire)
Aug-10-23 02:28PM	FMR LLC Reduces Stake in Day One Biopharmaceuticals Inc (GuruFocus.com)
Aug-07-23 04:30PM	Day One Reports Second Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire) +5.66%
Jun-17-23 08:29AM	Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) is favoured by institutional owners who hold 54% of the company (Simply Wall St.)
Jun-12-23 08:00AM	Day One Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Jun-08-23 12:38PM	Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More (Zacks) -8.19%
07:00AM	KAZIA THERAPEUTICS ANNOUNCES PHASE II CLINICAL STUDY TO INVESTIGATE PAXALISIB IN RECURRENT/PROGRESSIVE IDH-MUTANT GRADE 2 & 3 GLIOMA (PR Newswire)
Jun-06-23 10:31PM	Day One Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:01PM	Day One Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-05-23 04:06PM	ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Dips (Investor's Business Daily)
12:30PM	Why Shares of Day One Pharmaceuticals Are Up Monday (Motley Fool)
Jun-04-23 12:45PM	Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (GlobeNewswire)
May-30-23 08:00AM	Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference (GlobeNewswire)
May-25-23 08:30PM	CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
05:00PM	Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-01-23 09:00AM	Day One Reports First Quarter 2023 Financial Results and Corporate Progress (GlobeNewswire) +16.69%

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Merendino Lauren	Chief Commercial Officer	May 16 '25	Sale	6.26	3,927	24,575	35,161	May 19 05:54 PM
Dubow Adam	GENERAL COUNSEL	May 16 '25	Sale	6.26	4,552	28,486	47,136	May 19 05:48 PM
York Charles N II	COO, CFO AND SECRETARY	May 16 '25	Sale	6.26	4,282	26,796	265,231	May 19 05:45 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 16 '25	Sale	6.26	13,964	87,385	145,737	May 19 05:44 PM
CHARLES YORK	Officer	May 16 '25	Proposed Sale	6.26	4,282	26,796		May 16 04:09 PM
LAUREN MERENDINO	Officer	May 16 '25	Proposed Sale	6.26	3,927	24,575		May 16 04:09 PM
ADAM DUBOW	Officer	May 16 '25	Proposed Sale	6.26	4,552	28,486		May 16 04:08 PM
JEREMY BENDER	Officer	May 16 '25	Proposed Sale	6.26	13,964	87,385		May 16 04:08 PM
York Charles N II	COO, CFO AND SECRETARY	Feb 18 '25	Sale	11.96	4,370	52,278	252,638	Feb 21 06:10 PM
Dubow Adam	GENERAL COUNSEL	Feb 18 '25	Sale	11.96	4,646	55,580	39,602	Feb 21 06:08 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	11.96	12,048	144,130	128,015	Feb 21 06:05 PM
ADAM DUBOW	Officer	Feb 18 '25	Proposed Sale	11.96	4,646	55,580		Feb 18 06:07 PM
CHARLES YORK	Officer	Feb 18 '25	Proposed Sale	11.96	4,370	52,278		Feb 18 06:04 PM
JEREMY BENDER	Officer	Feb 18 '25	Proposed Sale	11.96	12,048	144,129		Feb 18 06:02 PM
Blackman Samuel C.	HEAD OF R&D	Dec 10 '24	Sale	13.31	30,000	399,339	1,034,015	Dec 12 04:06 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Nov 18 '24	Sale	13.21	10,554	139,420	108,377	Nov 19 04:36 PM
Blackman Samuel C.	HEAD OF R&D	Nov 18 '24	Sale	13.21	2,206	29,142	1,064,015	Nov 19 04:34 PM
Dubow Adam	GENERAL COUNSEL	Nov 18 '24	Sale	13.21	3,165	41,810	32,162	Nov 19 04:32 PM
York Charles N II	COO, CFO AND SECRETARY	Nov 18 '24	Sale	13.21	2,602	34,373	240,133	Nov 19 04:30 PM
SAMUEL BLACKMAN	Officer	Nov 18 '24	Proposed Sale	13.21	2,206	29,142		Nov 18 04:22 PM
JEREMY BENDER	Officer	Nov 18 '24	Proposed Sale	13.21	10,554	139,420		Nov 18 04:21 PM
Blackman Samuel C.	HEAD OF R&D	Nov 08 '24	Sale	16.17	18,255	295,229	1,067,535	Nov 12 04:57 PM
Blackman Samuel C.	HEAD OF R&D	Nov 11 '24	Sale	16.10	10,000	160,994	1,057,535	Nov 12 04:57 PM
SAMUEL BLACKMAN	Officer	Nov 11 '24	Proposed Sale	16.39	50,000	819,500		Nov 12 07:49 AM
Blackman Samuel C.	HEAD OF R&D	Nov 07 '24	Sale	16.03	11,245	180,287	1,085,790	Nov 08 04:15 PM
Blackman Samuel C.	HEAD OF R&D	Oct 31 '24	Sale	16.02	500	8,010	1,097,035	Nov 04 05:24 PM
SAMUEL BLACKMAN	Officer	Oct 31 '24	Proposed Sale	14.47	30,000	434,100		Oct 31 04:27 PM
Blackman Samuel C.	HEAD OF R&D	Sep 10 '24	Sale	14.22	30,000	426,675	1,097,535	Sep 12 04:48 PM
Dubow Adam	GENERAL COUNSEL	Aug 16 '24	Sale	14.00	3,202	44,825	26,928	Aug 19 06:12 PM
York Charles N II	COO, CFO AND SECRETARY	Aug 16 '24	Sale	14.00	2,633	36,860	232,485	Aug 19 06:07 PM
Blackman Samuel C.	HEAD OF R&D	Aug 16 '24	Sale	14.00	2,232	31,246	1,127,535	Aug 19 05:59 PM
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Aug 16 '24	Sale	14.00	10,681	149,524	98,932	Aug 19 05:53 PM
JEREMY BENDER	Officer	Aug 16 '24	Proposed Sale	14.00	10,681	149,524		Aug 16 05:23 PM
SAMUEL BLACKMAN	Officer	Aug 16 '24	Proposed Sale	14.00	2,232	31,246		Aug 16 05:17 PM
Blackman Samuel C.	HEAD OF R&D	Jul 16 '24	Sale	16.01	20,000	320,226	1,121,081	Jul 17 04:53 PM
Ramasastry Saira	Director	Jun 21 '24	Sale	13.19	10,000	131,877	40,485	Jun 21 07:17 PM
Blackman Samuel C.	HEAD OF R&D	Jun 10 '24	Sale	12.62	30,000	378,588	1,141,081	Jun 12 04:29 PM

Dollar change +0.30
Percentage change 5.83	%

VIR Vir Biotechnology Inc daily Stock Chart

Peers: REGN MRNA LLY PFE JNJ GILD BNTX AZN SNY NVAX

| Held by: IJR VTI VB IWM XBI VBK VXF IJS IWN SPSM

Index	RUT	P/E	-	EPS (ttm)	-4.22	Insider Own	35.56%	Shs Outstand	138.06M	Perf Week	10.32%
Market Cap	753.40M	Forward P/E	-	EPS next Y	-3.08	Insider Trans	-0.33%	Shs Float	89.08M	Perf Month	-2.85%
Income	-577.65M	PEG	-	EPS next Q	-0.74	Inst Own	53.56%	Short Float	12.28%	Perf Quarter	-31.53%
Sales	20.86M	P/S	36.12	EPS this Y	16.37%	Inst Trans	6.07%	Short Ratio	8.08	Perf Half Y	-40.76%
Book/sh	7.56	P/B	0.72	EPS next Y	3.70%	ROA	-37.25%	Short Interest	10.94M	Perf Year	-48.49%
Cash/sh	6.44	P/C	0.85	EPS next 5Y	10.19%	ROE	-44.59%	52W Range	4.32 - 14.45	Perf YTD	-25.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.74%	ROI	-51.03%	52W High	-62.28%	Beta	1.23
Dividend TTM	-	Quick Ratio	6.79	Sales past 5Y	55.77%	Gross Margin	34.35%	52W Low	26.16%	ATR (14)	0.32
Dividend Ex-Date	Nov 03, 2010	Current Ratio	6.79	EPS Y/Y TTM	-5.24%	Oper. Margin	-2796.93%	RSI (14)	55.31	Volatility	3.45% 4.76%
Employees	408	Debt/Eq	0.09	Sales Y/Y TTM	-73.79%	Profit Margin	-2769.04%	Recom	1.56	Target Price	17.88
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	-82.36%	Payout	-	Rel Volume	0.98	Prev Close	5.15
Sales Surprise	-64.71%	EPS Surprise	-5.30%	Sales Q/Q	-94.62%	Earnings	May 07 AMC	Avg Volume	1.35M	Price	5.45
SMA20	11.85%	SMA50	-0.51%	SMA200	-28.43%	Trades		Volume	1,332,434	Change	5.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight	$26
Mar-13-20	Downgrade	Goldman	Buy → Neutral

Show Previous Ratings

May-28-25 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Business Wire) +9.03%
May-20-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit (Business Wire)
May-12-25 04:05PM	Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference (Business Wire) -11.32%
May-09-25 06:00AM	Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study (Business Wire) -6.01%
May-08-25 09:35AM	Q1 2025 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
03:31AM	Loading…
03:31AM	Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 11:21PM	Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus (Seeking Alpha)
11:21PM	Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:15PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results (Business Wire)
Apr-30-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 (Business Wire)
11:45AM	GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance (Zacks)
Apr-24-25 09:30AM	Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 (Business Wire) +5.36%
Apr-09-25 09:43AM	Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple (Insider Monkey) +10.21%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	Loading…
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 07:10AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results (PR Newswire)
Mar-13-25 08:05AM	Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -11.85%
02:24AM	Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
Feb-26-25 05:45PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-19-25 04:05PM	Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-12-25 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 (Business Wire) +5.16%
Jan-23-25 06:35PM	Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now (Insider Monkey) +6.36% -5.09%
Jan-10-25 02:32PM	Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why (Benzinga)
Jan-09-25 08:30AM	Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20 (Investing.com)
08:18AM	Vir Biotechnology Reports Promising Trial Results for Cancer Therapies (TipRanks)
Jan-08-25 04:06PM	Vir Biotechnology Catapults 58% On Promising Results In Cancer Treatment (Investor's Business Daily) +58.17%
07:45AM	Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC (Business Wire)
07:25AM	Loading…
07:25AM	Vir Biotechnology price target lowered to $14 from $15 at BofA (TipRanks)
Dec-18-24 09:30AM	Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 04:05PM	Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta (Business Wire)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +12.88% -8.97%
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
Nov-26-24 09:30AM	Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN Masked T-Cell Engager Programs (Business Wire)
Nov-25-24 09:30AM	Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-18-24 09:15PM	Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program (Business Wire) -12.23%
04:05PM	Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency (Business Wire)
Nov-15-24 01:39PM	What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? (Benzinga) -7.29%
11:00AM	Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting (Business Wire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +23.63%
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 05:20PM	Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (Business Wire)
Oct-18-24 03:04PM	State Street Corp's Strategic Acquisition in Vir Biotechnology Inc (GuruFocus.com)
Oct-17-24 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 (Business Wire)
Oct-15-24 08:16AM	Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 (Business Wire)
Oct-03-24 04:00PM	Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (Business Wire) +5.59%
Sep-10-24 08:05AM	Vir Biotechnology Appoints Jason OByrne as Chief Financial Officer (Business Wire)
Sep-09-24 04:05PM	Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers (Business Wire)
Sep-04-24 08:30AM	Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 (GlobeNewswire)
Aug-22-24 08:05AM	Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-06-24 09:55AM	Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? (Zacks)
Aug-01-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.34%
04:02PM	Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities (Business Wire)
04:01PM	Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers (Business Wire)
Jul-18-24 04:05PM	Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 (Business Wire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
Jun-26-24 08:05AM	Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection (Business Wire)
Jun-06-24 01:26PM	Vir Biotechnology (VIR) Up on Positive Data From HDV Study (Zacks) -5.37%
Jun-05-24 02:51PM	Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? (Benzinga) +19.66%
05:30AM	Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment (Business Wire)
May-29-24 04:05PM	Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire) -5.87%
08:05AM	Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer (Business Wire)
May-23-24 04:05PM	Vir Biotechnology to Host 2024 Annual Meeting of Stockholders (Business Wire) -6.33%
May-22-24 08:05AM	Multiple Abstracts Highlighting Vir Biotechnologys Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024 (Business Wire) +11.36%
May-21-24 08:17AM	Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024 (Business Wire) +5.37%
May-13-24 07:21PM	Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies (PR Newswire)
May-09-24 10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 09:55AM	Wall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet (Zacks)
May-03-24 01:05PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript (Insider Monkey) +13.18%
06:05AM	Q1 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 09:56PM	VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 (InvestorPlace) +5.03%
06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 04:05PM	Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 (Business Wire)
Apr-24-24 12:00PM	What Makes Vir Biotechnology (VIR) a New Buy Stock (Zacks)
Apr-18-24 08:00AM	Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (Business Wire)
Apr-11-24 04:30PM	Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Apr-04-24 07:01PM	Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares (GuruFocus.com)
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Mar-19-24 02:58PM	From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires (InvestorPlace) -6.37%
Mar-13-24 11:07AM	Billionaires Biotech Bets: 3 Stocks Dominating Bill Gates Portfolio (InvestorPlace)
Mar-05-24 08:05AM	Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule (Business Wire)
Feb-23-24 01:54PM	Q4 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +11.94%
10:34AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade (Zacks)
08:05AM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-22-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:30PM	Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer (Business Wire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.62%
Feb-01-24 04:05PM	Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 (Business Wire)
Jan-15-24 11:32AM	Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why (Zacks)
Dec-17-23 07:00AM	I See a Vir-y Good Trade (TheStreet.com)
07:00AM	I See a Good Trade on a $10 Biotech Stock (TheStreet.com)
Dec-13-23 04:05PM	Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation (Business Wire) +9.11%
Dec-06-23 04:05PM	Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference (Business Wire)

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Napolitano Janet	Director	Jun 02 '25	Sale	5.05	3,200	16,149	16,416	Jun 02 07:26 PM
JANET ANN NAPOLITANO	Director	Jun 02 '25	Proposed Sale	4.94	3,200	15,808		Jun 02 04:29 PM
De Backer Marianne	Chief Executive Officer	Apr 03 '25	Sale	5.95	79,712	474,239	769,505	Apr 04 04:23 PM
Marianne De Backer	Officer and Director	Apr 03 '25	Proposed Sale	5.95	79,712	474,239		Apr 03 07:50 PM
de Verneuil Vanina	EVP and General Counsel	Feb 26 '25	Sale	9.14	7,373	67,402	79,460	Feb 27 12:39 PM
VANINA DE VERNEUIL	Officer	Feb 26 '25	Proposed Sale	9.10	7,373	67,094		Feb 26 04:23 PM
SCANGOS GEORGE A	Director	Feb 24 '25	Sale	9.45	10,056	95,063	698,239	Feb 25 03:44 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 24 '25	Sale	9.45	14,168	133,936	117,901	Feb 25 03:43 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 24 '25	Sale	9.45	1,562	14,766	46,627	Feb 25 03:37 PM
De Backer Marianne	Chief Executive Officer	Feb 24 '25	Sale	9.45	16,122	152,408	849,217	Feb 25 03:36 PM
de Verneuil Vanina	EVP and General Counsel	Feb 24 '25	Sale	9.45	5,140	48,590	86,833	Feb 25 03:34 PM
George Scangos	Director	Feb 24 '25	Proposed Sale	9.45	10,056	95,063		Feb 24 08:57 PM
Brent Sabatini	Officer	Feb 24 '25	Proposed Sale	9.45	1,562	14,766		Feb 24 08:57 PM
Ann Hanly	Officer	Feb 24 '25	Proposed Sale	9.45	14,168	133,936		Feb 24 08:56 PM
Vanina de Verneuil	Officer	Feb 24 '25	Proposed Sale	9.45	5,140	48,590		Feb 24 08:40 PM
Marianne De Backer	Officer and Director	Feb 24 '25	Proposed Sale	9.45	16,122	152,408		Feb 24 08:38 PM
SCANGOS GEORGE A	Director	Feb 18 '25	Sale	9.81	10,964	107,575	708,295	Feb 19 07:11 PM
George Scangos	Director	Feb 18 '25	Proposed Sale	9.81	10,964	107,575		Feb 18 07:50 PM
Sabatini Brent	SVP, Chief Accounting Officer	Feb 13 '25	Sale	9.15	1,562	14,291	28,189	Feb 14 06:41 PM
Brent Sabatini	Officer	Feb 13 '25	Proposed Sale	9.15	1,562	14,291		Feb 13 06:49 PM
SATO VICKI L	Director	Jan 08 '25	Sale	12.52	10,960	137,219	1,312,391	Jan 08 08:03 PM
VICKI LEE SATO	Director	Jan 08 '25	Proposed Sale	7.89	43,840	345,898		Jan 08 04:22 PM
de Verneuil Vanina	EVP and General Counsel	Dec 02 '24	Sale	8.22	76	625	56,973	Dec 04 03:35 PM
VANINA ALEXANDRA HUARD DE VERN	Officer	Dec 02 '24	Proposed Sale	8.22	76	625		Dec 02 05:08 PM
de Verneuil Vanina	EVP and General Counsel	Nov 06 '24	Sale	10.11	4,397	44,454	56,973	Nov 07 07:20 PM
VANINA DE VERNEUIL	Officer	Nov 06 '24	Proposed Sale	9.64	4,397	42,387		Nov 06 04:55 PM
de Verneuil Vanina	EVP and General Counsel	Nov 05 '24	Sale	9.47	2,347	22,225	61,370	Nov 05 05:51 PM
de Verneuil Vanina	EVP and General Counsel	Nov 01 '24	Sale	7.20	1,403	10,107	63,717	Nov 05 05:51 PM
VANINA DE VERNEUIL	Officer	Nov 05 '24	Proposed Sale	9.37	2,347	21,991		Nov 05 04:23 PM
Napolitano Janet	Director	Sep 09 '24	Sale	7.80	12,190	95,032	11,616	Sep 10 04:28 PM
JANET ANN NAPOLITANO	Director	Sep 09 '24	Proposed Sale	7.76	12,190	94,594		Sep 09 04:29 PM
Ramasastry Saira	Director	Jun 11 '24	Sale	10.95	4,000	43,789	14,619	Jun 12 12:21 PM

MIRM

Mirum Pharmaceuticals Inc

DAWN

Day One Biopharmaceuticals Inc

VIR

Vir Biotechnology Inc

Upgrade your FINVIZ experience